×

Novel Immuno-oncology Biomarker Testing Market Report


Company Analysis, History and Future Overview, Global Sales Trends by 2025


Published Date: 2019-08-21   |   Pages: Ongoing   |   Tables: Ongoing   |  Report ID: 7348 |  Industry: Miscellaneous  |   Format : pdf word ppt excel



   Request Sample     Request Customization    Request Methodology
  • SELECT LICENSE TYPE :

  •   Single License
  •  Multi User License
  •  Corporate License


Demand for novel immuno-oncology biomarker testing is foreseen to show growth on the back of the rising need for high success rates of cancer treatments and clinical cancer researches. There are various anti-cancer vaccines, immunotherapies, and targeted therapies available for cancer treatment. However, physicians and researchers have grappled with major obstacles such as treatment-based adverse effects and drug-related limitations. This where the role of multiple novel biomarkers comes into play. Today, scientists are able to identify advanced cancer biomarkers with the help of biotechnological advancement.

Cancer Research Initiatives to Work in Favor of Global Market

Increasing investigation of mismatch repair deficiency, microsatellite instability, tumor mutation burden, and other novel cancer biomarkers is predicted to highlight the global novel immuno-oncology biomarker testing market. Rising number of clinical research initiatives for studying the application and relevance of several novel cancer biomarkers could augur well for the global market. Need to make personalized cancer treatment-related decisions is encouraging the development of analytical tests for cancer biomarkers.

Oncology Testing and Service Deals to Give Strength to Product Portfolio

Some of the leading players of the global novel immuno-oncology biomarker testing market are Agilent Technologies, Inc., Biodesix, Eli Lilly and Company, AstraZeneca, Ventana Medical Systems, Inc., Genentech Inc., Bristol-Myers Squibb, Merck & Co., Inc., and Pfizer Inc. Besides collaboration, acquisition is a powerful strategy that could help players to gain a significant share of the global market. In July 2019, Interpace Diagnostics Group, a US provider of clinically useful molecular and related first-line diagnostic tests for evaluating cancer risk, signed the acquisition of the biopharma services business of Cancer Genetics, Inc., a US DNA-based cancer diagnostics company.

By Testing Method

   Tumor Infiltrating Lymphocytes (TILs)

   Microsatellite Instability

   Tumor Mutational Burden

   Others

By Application

   Blood Cancer

   Colon Cancer

   Prostate Cancer

   Colorectal Cancer

   Melanoma

   Lung Cancer

   Others

By Technology Type

   Immunohistochemistry

   Next-generation Sequencing

   Polymerase Chain Reaction

   Others

By End Use

   Research Use

   Clinical Use

   Commercial Use

The market share of research use is expected to increase in future as growing number of immuno-oncology and cancer diagnostics companies continue to partner with each other. In July 2019, Immodulon Therapeutics Ltd., a UK-based clinical-stage immuno-oncology company, and Biodesix Inc., a US molecular diagnostics company, formed a biomarker research partnership focusing on pancreatic cancer treatment.

Immunohistochemistry is a popular technology used in the global novel immuno-oncology biomarker testing market. In July 2019, a top-performing series of immunohistochemistry antibodies called PathPlus was released by LifeSpan BioSciences, Inc., a US provider of enzyme-linked immunosorbent assay kits, biochemicals, proteins, and antibodies. These antibodies will be used to detect 200 high-value cancer targets.

TILs are increasingly adopted in cancer therapy research and development mainly because of the versatility and potential of T cells. In May 2019, Iovance Biotherapeutics, Inc., a US developer of novel cancer immunotherapies based on TILs, announced an objective response rate of 44% in advanced cervical cancer patients treated with TIL therapy LN-145. The company also announced an objective response rate of 38% in advanced melanoma patients treated with TIL therapy lifileucel.

By Region

High number of collaborations and partnerships focusing on the development of effective oncology treatments is anticipated to push the demand in the North America novel immuno-oncology biomarker testing market. In July 2019, Freenome, a US AI genomics biotech company, closed its Series B financing of $160 million to help advance its multi-omics blood testing platform for early cancer detection.

Increasing research on blood cancer treatments is expected to draw the attention to novel immuno-oncology biomarker testing in North America. In July 2019, the UNC Lineberger Comprehensive Cancer Center, a US cancer research and treatment center, developed an experimental therapeutic compound to block a hyperactive cell signal contributing to tumor growth in primary effusion lymphoma, a type of blood cancer.

Agriculture


Agriculture is expected to be an important sector of the global business in the coming years. At QYR Consulting we make sincere efforts to help you improve your performance and transform your business by seizing the opportunities. Our research reports include an assessment of the shifting agricultural trends, evolving energy needs, and introduction of disruptive technologies. We offer market outlooks after through research, which is conducted using primary and secondary research methodologies.

Our reports highlight the best investment opportunities by evaluating the risk factors. Over a period of time, we have built a valuable network of market experts, which makes its own, invaluable contribution in writing these business reports. With our understanding of the promising markets, we present to you a heuristic approach towards discovering the future of energy and agriculture sector.


Energy and Power


Energy and power systems across the globe have undergone massive changes in recent years. The surging demand for power consumption has drastically impacted generation and distribution of energy through the years. The changing landscape, with innovation in automotive, housing, and industrial sectors, has pushed energy and power companies to not just boost production but also look for alternatives for sustainability. The sector is challenged by issues of soaring demand and rising CO2 emissions.

The research reports shed light on the energy and power needs of the future. They predict the rise and fall from conventional energy consumption to renewable power production. Analysts have discussed the benefits and hurdles that energy mixes are expected to bring. Wind, solar, and other renewable and less harmful energy sources have been extensively researched and written about in these research reports.


Service and Software


The software industry has reinvented the future of business over the years. From providing top-notch solutions to customizing them for specific needs, the software industry offers myriad services. Shifting trends and needs of the global citizens has drastically helped the service and software industry as devised applications that were unheard of. We understand your changing needs that demand unique vision and strategy.


The software industry has reinvented the future of business over the years. From providing top-notch solutions to customizing them for specific needs, the software industry offers myriad services. Shifting trends and needs of the global citizens has drastically helped the service and software industry to devise applications that were unheard of. We understand your changing needs that demand unique vision and strategy.

The research reports have been collated by an expert team of analysts who aim to be your guiding hand through the coming years. The thoughtful evaluation of the service and software industry attempts to provide a detailed picture of the changing competitive landscape. Analysts have discussed products and evaluated the way they must progress to stay ahead of the game.

Request for Table of Contents



  You must accept our privacy policies before submit your requirement




Why QYR Consulting?


We are committed to delivering the best solutions and we offer a 24*7 helpline.


We promise superior quality of authenticated data.


We offer help and advice across varying time zones.


We boast a strong team of experienced analysts.


We have an exhaustive repository of published reports.


Read More

Contact us Directly

USA
 +1 626 428 8800

India
  +91 20 67104444

Beijing
  +86 108 294 5717

For Enquiry : sales@qyrconsulting.com

Request for Tables



  You must accept our privacy policies before submit your requirement




Why QYR Consulting?


We are committed to delivering the best solutions and we offer a 24*7 helpline.


We promise superior quality of authenticated data.


We offer help and advice across varying time zones.


We boast a strong team of experienced analysts.


We have an exhaustive repository of published reports.


Read More

Contact us Directly

USA
 +1 626 428 8800

India
  +91 20 67104444

Beijing
  +86 108 294 5717

For Enquiry : sales@qyrconsulting.com

Request for Figures



  You must accept our privacy policies before submit your requirement




Why QYR Consulting?


We are committed to delivering the best solutions and we offer a 24*7 helpline.


We promise superior quality of authenticated data.


We offer help and advice across varying time zones.


We boast a strong team of experienced analysts.


We have an exhaustive repository of published reports.


Read More

Contact us Directly

USA
 +1 626 428 8800

India
  +91 20 67104444

Beijing
  +86 108 294 5717

For Enquiry : sales@qyrconsulting.com

Reasons to Buy this Report



Fastest report delivery

Fastest report delivery

We have the fastest report delivery service with excellent after-sales support

 

In-depth analysis

In-depth analysis

We provide a comprehensive and in-depth analysis in every report that we sell

 

Large database

Large database

We own large database which will help our clients to get customized and syndicated research reports

 

Accurate data

Accurate data

To offer you accurate data, our seasoned analysts will be available to assist you

 


 

Ask a Question

Get in touch with us to find answers to all your business-related queries for fast results.

 

NOTE - The analysis, thoughts, views, facts, and opinions expressed in this report are of the respective research analysts.QYR Consulting does not necessarily endorse it or it is also not essentially formal views of QYR Consulting.



Novel Immuno-oncology Biomarker Testing Market Report